
Alivus Life Sciences Analyst Review 2027: Profit Jumps 51% as Stock Runs Past Broker Target
Updated: 18 Nov 2026 • 3:06 pm
Posted by:

Alivus Life Sciences Stock Snapshot (17 Nov 2026 close)
- Current Market Price (CMP): ₹1,447.80
- 52-Week High / Low: ₹1,574.00 / ₹819.00
- Market Capitalisation: ₹17,801 crore
- P/E Ratio vs Industry P/E: 26.6 vs 51.5
- Latest Quarter (Q2 FY27) Revenue: ₹682 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹196.7 crore
Quick Answer: The Alivus Life Sciences analyst review 2027 shows a strong quarter and a stock that has outrun its only verified target. Q2 FY27 revenue rose about 16% to ₹682 crore, EBITDA rose about 47% and net profit rose about 51% to ₹196.7 crore, with a reported EBITDA margin of 41.8%. ICICI Securities has a Buy rating with a ₹1,330 target from July 2026, about 8% below the ₹1,447.80 close. At a P/E near 26.6 against an industry figure of about 51.5, the Alivus share price target 2027 debate turns on whether margins stay well above the 35% to 36% guidance.
The Alivus Life Sciences analyst review 2027 covers the active pharmaceutical ingredient maker once known as Glenmark Life Sciences, now controlled by Nirma. The company makes APIs for chronic therapies and runs a fast-growing contract manufacturing arm. Readers searching for an Alivus share price target 2027 will find one named brokerage number, and the stock has already crossed it.
Alivus Life Sciences closed at ₹1,447.80 on 17 November 2026. That is about 8% below its 52-week high of ₹1,574 and about 77% above its low of ₹819. This Alivus Life Sciences analyst review 2027 sets out what the brokerage expects, what the September quarter delivered and what will shape the Alivus stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the Alivus Life Sciences Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| ICICI Securities | Buy | ₹1,330 | July 2026 |
ICICI Securities set its ₹1,330 target in July 2026, valuing Alivus at 15 times estimated FY28 EBITDA. The brokerage case was built on steady API growth, a rising share of business from customers outside Glenmark and a debt-free balance sheet.
The stock has since moved about 8% above that target. That does not make the target wrong, but it means the market is now pricing in more than the July estimates. A higher number after the Q2 beat would be the next signal for the Alivus share price target 2027. Until then, the Alivus Life Sciences analyst review 2027 has no named target above the current price.
Q2 FY27 Results in the Alivus Life Sciences Analyst Review 2027
| Metric | Q2 FY27 | Change from Q2 FY26 |
|---|---|---|
| Revenue from operations | ₹682 crore | Up about 16% |
| EBITDA | Margin 41.8% (about 39.5% adjusted) | Up about 47% |
| Net profit | ₹196.7 crore | Up about 51.3% |
| Non-GPL business | 79% of revenue | Up about 20.8% |
| Generic API sales | Core segment | Up about 11% |
| CDMO sales | Growth segment | Up about 79.9% |
Revenue rose about 16% to ₹682 crore. EBITDA grew about 47%, much faster than sales, and the reported margin reached 41.8%. Stripping out one-off items, the margin was about 39.5%, still well above the company's own FY27 guidance of 35% to 36%.
Net profit rose about 51.3% to ₹196.7 crore. Sales to customers other than Glenmark Pharmaceuticals rose about 20.8% and now make up 79% of revenue, which reduces dependence on the former parent. For the Alivus Life Sciences analyst review 2027, this is the cleanest quarter the company has posted since the change in ownership.
How Alivus Life Sciences Makes Money
Alivus sells pharmaceutical ingredients to drug makers in India, the US, Europe and other regulated markets. Its earnings come from three streams.
- Generic APIs: ingredients for chronic therapies such as cardiovascular, diabetes, central nervous system and pain medicines. This is the bulk of revenue and grew about 11% in Q2.
- CDMO: contract development and manufacturing for innovator and specialty drug companies. Sales rose about 79.9% in Q2 from a small base.
- Glenmark supply: APIs sold to Glenmark Pharmaceuticals under a supply arrangement, now 21% of revenue.
Nirma took control of the company from Glenmark Pharmaceuticals and renamed it Alivus Life Sciences. Nirma now holds 74.85%. The ownership change shifted the focus towards outside customers, a trend visible across every quarter of the Alivus Life Sciences analyst review 2027.
Growth Triggers in the Alivus Life Sciences Analyst Review 2027
- CDMO scale-up: about 80% growth in Q2 shows contract manufacturing becoming a real second engine.
- Customer diversification: non-Glenmark sales are now 79% of revenue and growing about 21%.
- Margin cushion: adjusted EBITDA margin near 39.5% is well above the 35% to 36% guidance.
- Guidance headroom: FY27 revenue growth guidance of 10% to 12% looks beatable after a 16% Q2.
- Debt-free balance sheet: debt to equity of about 0.01 funds capacity additions from cash, which supports the Alivus share price target 2027 case.
Key Risks in the Alivus Life Sciences Analyst Review 2027
- Price above target: the stock trades about 8% above ICICI Securities' ₹1,330 target.
- Margin normalisation: management guides to 35% to 36%, below the 41.8% reported in Q2.
- Price pressure in generics: generic API prices tend to fall over time as competition grows.
- Regulatory audits: US FDA and European inspections can delay supplies.
- Foreign selling: FII holding fell from 6.84% to 5.93% over the year, a caution in the Alivus Life Sciences analyst review 2027.
Compare Alivus Life Sciences With Other Pharma API Stocks on the Univest Screener
Alivus Life Sciences Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (17 Nov 2026 close) | ₹1,447.80 |
| 52-Week High / Low | ₹1,574.00 / ₹819.00 |
| Market Capitalisation | ₹17,801 crore |
| P/E (TTM) vs Industry | 26.6 vs 51.5 |
| Price to Book | 4.90 |
| Book Value per Share | ₹295.31 |
| Return on Equity | 18.44% |
| Debt to Equity | 0.01 |
| Dividend Yield | 0.34% |
| EPS (TTM) | ₹54.47 |
A P/E of about 26.6 is roughly half the pharma industry figure, while return on equity is about 18.4%. Price to book value is about 4.9. In the Alivus Life Sciences analyst review 2027, the multiple looks modest next to peers, which helps explain why the stock moved past its target. The Nifty Pharma index is a useful benchmark for sector sentiment.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters (Nirma) | 74.91% | 74.85% | Down 0.06 pts |
| Foreign Investors (FII) | 6.84% | 5.93% | Down 0.91 pts |
| Domestic Institutions (DII) | 5.47% | 7.03% | Up 1.56 pts |
| Public | 12.78% | 12.19% | Down 0.59 pts |
Nirma, the promoter, holds 74.85%, close to the 75% cap on promoter holding. Domestic institutions raised their stake by about 1.6 points while foreign investors trimmed theirs. Rising mutual fund interest is a support point in the Alivus Life Sciences analyst review 2027.
What to Watch After the Alivus Life Sciences Analyst Review 2027
- Margin path: whether EBITDA margin stays near 40% or moves back to the 35% to 36% guide.
- CDMO orders: new contract wins and the pace of CDMO revenue growth.
- Full-year growth: whether FY27 revenue growth beats the 10% to 12% guidance.
- Plant audits: outcomes of regulatory inspections at its API sites.
- Target revisions: any upgrade above ₹1,330 would reset the Alivus share price target 2027.
Final Word on the Alivus Life Sciences Analyst Review 2027
The Alivus Life Sciences analyst review 2027 shows a debt-free API maker with profit up about 51%, margins well above guidance and a growing CDMO arm. The stock trades at about half the industry P/E but already sits above the only verified brokerage target.
The Alivus stock outlook 2027 depends on margin durability, CDMO growth and the pace of outside-customer wins. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Alivus Life Sciences analyst review 2027 show?
It shows strong growth and margins well above guidance. Q2 FY27 revenue rose about 16% to ₹682 crore and profit rose about 51% to ₹196.7 crore. Reported EBITDA margin was 41.8%. The stock trades above its only verified target.
What is the Alivus share price target 2027 from brokerages?
ICICI Securities has a Buy rating with a ₹1,330 target from July 2026. It values the company at 15 times estimated FY28 EBITDA. The stock closed at ₹1,447.80 on 17 November 2026, about 8% above that target.
Is Alivus Life Sciences the same as Glenmark Life Sciences?
Yes, Alivus Life Sciences is the new name of Glenmark Life Sciences. Nirma took control from Glenmark Pharmaceuticals and now holds 74.85%. Sales to Glenmark are now about 21% of revenue.
How does Alivus Life Sciences make money?
It sells generic APIs for chronic therapies and runs a CDMO business. Generic API sales grew about 11% in Q2 FY27. CDMO sales grew about 79.9%. Non-Glenmark business made up 79% of revenue.
Is Alivus stock expensive based on the Alivus Life Sciences analyst review 2027?
The P/E of about 26.6 is roughly half the industry figure of about 51.5. Return on equity is about 18.4% and debt to equity is about 0.01. Price to book is about 4.9.
What risks does the Alivus Life Sciences analyst review 2027 highlight?
The main risk is that margins fall from 41.8% towards the 35% to 36% guidance. The stock also trades about 8% above ICICI Securities' target. Foreign investors cut their stake from 6.84% to 5.93% over the year.
What should investors track after the Alivus Life Sciences analyst review 2027?
Track whether EBITDA margin stays near 40% in the December quarter. Watch CDMO order wins and whether FY27 revenue growth beats the 10% to 12% guidance. Regulatory audit outcomes at its plants also matter.
Recent Articles

Stock Market Today: Share Market Live Updates, Sensex and Nifty 50 Today
18 November 2026

Surana Telecom and Power Share Price Target 2027: 23.8% Upside to Rs 18.6, Bull Rs 22.3
18 November 2026

HDFC Life Insurance Share Price Target 2027: Rs 653 Base, Rs 793 Bull and the Risks to Watch
18 November 2026

Ceinsys Tech Share Price Target 2027: Is Rs 788 Realistic? Bull Case Points to Rs 944
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Stock Market Today: Share Market Live Updates, Sensex and Nifty 50 Today
Surana Telecom and Power Share Price Target 2027: 23.8% Upside to Rs 18.6, Bull Rs 22.3
HDFC Life Insurance Share Price Target 2027: Rs 653 Base, Rs 793 Bull and the Risks to Watch
Ceinsys Tech Share Price Target 2027: Is Rs 788 Realistic? Bull Case Points to Rs 944
Bodhi Tree Multimedia Share Price Target 2027: Can It Reach Rs 8.64? Base Case at Rs 7.26

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





